West Pharmaceutical Services Inc. (WST)

West Pharmaceutical Services is trading near the top of its 52-week range, at $412.86 and 5.80% below its 52-week high of $438.27. The stock sits above its 20-day EMA, 50-day SMA and 200-day SMA, and the 50-day average is 18.06% above the 200-day average, so the trend is up on every average CleaRank tracks. The rally follows a second-half 2026 earnings record of eight straight beats, the latest on October 29, 2026, when adjusted EPS of $2.66 topped the $2.20 estimate by 20.91%. The question for investors now is whether earnings growth can keep pace with a valuation that already sits well above the sector.

West reported adjusted EPS of $2.66 on October 29, 2026, against an analyst estimate of $2.20, a beat of 20.91%. The shares rose 3.23% in the first session after the report. It was the eighth consecutive quarter in which the company beat the EPS estimate, and the record covers every report in the sample. The beats have not all been rewarded: four of the eight were followed by a lower share price in the first session, so the reaction to results has varied even as the earnings have consistently beaten the consensus.

Four firms kept their ratings on October 30, 2026: Citigroup and TD Cowen kept Buy ratings, Barclays kept an Overweight rating and Evercore ISI Group kept an Outperform rating. TD Cowen and Barclays had also reaffirmed their ratings earlier in October. Of 16 analysts with a current rating, 15 rate the stock Buy and one rates it Sell, while three months ago 14 of 16 rated it Buy. The sell-side view has therefore held firm and, if anything, is slightly more positive than in August.

At a trailing P/E of 46.41, the stock trades a premium to peers against a sector median of 31.9, which is 45.5% higher. Its price-to-sales ratio of 8.48 compares with a sector median of 3.4. The valuation is supported by reported earnings: GAAP EPS over the last 12 months is $8.91, and the operating margin of 22.88% and return on equity of 21.23% are both well above the sector. Debt-to-equity of 0.11 leaves the balance sheet with little leverage. Insiders made four sales worth $6.6M over the past 18 months and made no open-market purchases; such sales are often planned in advance or made to cover tax on vesting shares, so they carry less signal than purchases would.

The base case is that WST keeps its uptrend while earnings keep meeting or beating estimates. Analysts expect EPS to rise 29.8% this fiscal year to $9.46 and another 9.8% next year to $10.39, and revenue is expected to grow 11.3% to $3.4B this year. Fifteen of the 16 analysts rate the stock Buy, and the median 12-month target is $480.00, 16.3% above the price, with a range of $340.00 to $500.00. Those targets assume the growth plan is delivered, which is the main condition. The stock would be better supported if the next report confirms the pace of revenue growth, which ran at 13.80% in the latest quarter. It would be weaker if growth slows toward the sector median of 8.1%, or if a 46.41 trailing P/E, against a sector median of 31.9, starts to compress as expectations reset. The stock's typical daily move of 1.52% and beta of 1.14 mean sharp swings are normal for this name in either direction.

Support sits first at the 20-day EMA of $399.25, the nearest level below the price, which the stock has held as it climbed. Next is the 50-day SMA at $377.33, where the trend would be tested if the rally stalls. Further down, the 200-day SMA at $319.59 marks the long-term trend line, and the 52-week low of $223.83 is the floor of the past year's range. Resistance is the 52-week high of $438.27, the nearest level above the price and the point where the rally would meet its first ceiling. A move above it would mark a new 52-week high.